Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses the frontline treatment of patients with newly diagnosed ovarian cancer.
Paul Sabbatini, MD
Advertisement
Articles by Paul Sabbatini, MD
Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses promising therapies in newly diagnosed ovarian cancer.
Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses novel approaches for IP therapy for patients with ovarian cancer.
Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses the future of dose-dense therapy in ovarian cancer.
Advertisement
Latest Updated Articles
Dr. Sabbatini on the Future of Dose-Dense Therapy in Ovarian CancerPublished: November 9th 2017 | Updated:
Dr. Sabbatini on Novel Approaches With IP Therapy For Ovarian CancerPublished: November 30th 2017 | Updated:
Dr. Sabbatini on Promising Therapies in Newly Diagnosed Ovarian CancerPublished: May 2nd 2019 | Updated:
Dr. Sabbatini on Frontline Treatment of Newly Diagnosed Ovarian CancerPublished: May 24th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5